Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Board Appointments

Zhejiang Hisoar Pharmaceutical Co., Ltd. held its 1st Extraordinary General Meeting of 2025 on 18 November 2025, approved the appointment of Chen Guangshun, non-independent director, Chen Fangqi, non-independent director.

HISOAR released its performance for the first half of the year, with a net profit attributable to the parent company of 14.0937 million yuan, a decrease of 63.01%

HISOAR released its semi-annual report for 2025, with operating revenue of 925 million yuan, a year-on-year decrease of 10.94%; net profit attributable to the parent company of 14.0937 million yuan, a year-on-year decline of 63.01%; net profit excluding non-recurring gains and losses of 19.2833 million yuan, a year-on-year decrease of 37.50%; basic earnings per share of 0.01 yuan

A-share weight loss drug concept stocks continued to weaken in the afternoon, Menovo hit the limit down, Medicilon and Kanion Pharmaceutical fell over 7%, SDKX and HISOAR had the largest declines

HISOAR: First repurchase of 0.05% of the company's shares

HISOAR announced that on August 5, 2025, the company repurchased 850,000 shares through a dedicated securities account for stock repurchase via centralized bidding, accounting for 0.05% of the company's total share capital. The highest transaction price was RMB 6.29 per share, the lowest transaction price was RMB 6.24 per share, and the total transaction amount was RMB 5.3267 million. This repurchase complies with relevant laws and regulations and aligns with the established repurchase plan

HISOAR: The market holds an overall optimistic attitude towards the price recovery of Peinan products

HISOAR stated in its latest investor relations activity that the price of Peinan products has shown signs of recovery in the second quarter of this year after a continuous decline, and the market is optimistic about the restoration of its prices. The company maintains communication with global customers and suppliers, paying attention to whether the price can continue to recover. HISOAR has laid out in multiple fields such as anti-infection and blood sugar reduction, with related products at different stages of research and development, which is expected to broaden its development space in the future